KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Medpace Holdings (MEDP) over the last 9 years, with Sep 2025 value amounting to $285.4 million.

  • Medpace Holdings' Cash & Equivalents fell 56.56% to $285.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.4 million, marking a year-over-year decrease of 56.56%. This contributed to the annual value of $669.4 million for FY2024, which is 172.74% up from last year.
  • According to the latest figures from Q3 2025, Medpace Holdings' Cash & Equivalents is $285.4 million, which was up 515.91% from $46.3 million recorded in Q2 2025.
  • Medpace Holdings' 5-year Cash & Equivalents high stood at $669.4 million for Q4 2024, and its period low was $28.3 million during Q4 2022.
  • Its 3-year average for Cash & Equivalents is $313.1 million, with a median of $285.4 million in 2025.
  • Per our database at Business Quant, Medpace Holdings' Cash & Equivalents slumped by 93.87% in 2022 and then surged by 1,205.37% in 2024.
  • Medpace Holdings' Cash & Equivalents (Quarterly) stood at $461.3 million in 2021, then crashed by 93.87% to $28.3 million in 2022, then spiked by 768.38% to $245.4 million in 2023, then skyrocketed by 172.74% to $669.4 million in 2024, then crashed by 56.56% to $285.4 million in 2025.
  • Its Cash & Equivalents stands at $285.4 million for Q3 2025, versus $46.3 million for Q2 2025 and $441.4 million for Q1 2025.